
AffaMed Therapeutics, a global clinical stage biopharmaceutical company, has announced the appointment of Vijay Karwal as Chief Financial Officer. Reporting to AffaMed’s CEO Dr. Dayao Zhao, Mr. Karwal will be responsible for all aspects of financial management and will work closely with AffaMed’s leadership team. “We are extremely pleased to have Vijay join AffaMed at…